U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT06882785) titled 'A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia' on March 17.
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of KarXT in acutely psychotic Japanese adult participants with schizophrenia
Study Start Date: May 30
Study Type: INTERVENTIONAL
Condition:
Schizophrenia
Intervention:
DRUG: KarXT
Specified dose on specified days
OTHER: Placebo
Specified dose on specified days
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Bristol-Myers Squibb
Published by HT Digital Content Services with permission from Health Daily Digest....